PharmExec4d
Phase III Trial Data Show Uplizna Significantly Improves Symptoms of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
Zacks.com on MSN3d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...
BioSpace8d
Amgen’s Uplizna Deepens Response Against Myasthenia Gravis at 1 Year
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Clinical Trials Arena on MSN1d
Immunovant will not seek approval for MG therapy, despite hitting endpoints
The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
PMLiVE4d
Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study
Amgen has shared new data from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon) in adults with the rare autoimmune disorder generalised myasthenia gravis (gMG). The phase ...
pharmaphorum7d
Third indication beckons for Amgen's Uplizna
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
Endpoints News8d
Am­gen re­ports more Up­liz­na da­ta in myas­the­nia gravis ahead of FDA fil­ing
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...